|
| 35841248 | A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease. | J Prev Alzheimers Dis | 2022 |
| 33947447 | Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers. | Clin Epigenetics | 2021 |
| 34685549 | Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. | Cells | 2021 |
| 34280438 | Initial Findings from a High Genetic Risk Prostate Cancer Clinic. | Urology | 2021 |
| 29660369 | Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. | Urology | 2019 |
| 31641693 | The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study. | Diagn Progn Res | 2019 |
| 29713045 | Author Correction: Analysis of DNA methylation in cancer: location revisited. | Nat Rev Clin Oncol | 2018 |
| 29666440 | Analysis of DNA methylation in cancer: location revisited. | Nat Rev Clin Oncol | 2018 |
| 27756787 | A Four-Gene Promoter Methylation Marker Panel Consisting of <i>GREM1, NEURL, LAD1,</i> and <i>NEFH</i> Predicts Survival of Clear Cell Renal Cell Cancer Patients. | Clin Cancer Res | 2017 |
| 28370948 | Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. | BJU Int | 2017 |
| 28762545 | Epigenetic risk score improves prostate cancer risk assessment. | Prostate | 2017 |
| 27789672 | Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer. | Int J Epidemiol | 2017 |
| 27108162 | Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. | Eur Urol | 2016 |
| 26327355 | Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria. | J Urol | 2016 |
| 28066067 | CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. | Trans Am Clin Climatol Assoc | 2016 |
| 27121847 | Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. | Prostate | 2016 |
| 25204962 | We are all individuals... bioinformatics in the personalized medicine era. | Cell Oncol (Dordr) | 2015 |
| 25867767 | Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays. | Lab Invest | 2015 |
| 25904753 | Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. | Clin Cancer Res | 2015 |
| 25538088 | Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood. | Cancer Prev Res (Phila) | 2015 |
| 24241165 | Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. | Epigenetics | 2014 |
| 24991397 | Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. | Am Health Drug Benefits | 2014 |
| 24747657 | Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. | J Urol | 2014 |
| 24928946 | CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. | Clin Cancer Res | 2014 |
| 24398667 | Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. | Carcinogenesis | 2014 |
| 24486589 | Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. | Clin Cancer Res | 2014 |
| 22999998 | Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. | J Urol | 2013 |
| 24088737 | Novel methylation biomarker panel for the early detection of pancreatic cancer. | Clin Cancer Res | 2013 |
| 23929435 | An exploration of pathways involved in lung carcinoid progression using gene expression profiling. | Carcinogenesis | 2013 |
| 23630167 | Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. | Clin Cancer Res | 2013 |
| 23444222 | CD44 and OTP are strong prognostic markers for pulmonary carcinoids. | Clin Cancer Res | 2013 |
| 22161815 | The epigenetic promise for prostate cancer diagnosis. | Prostate | 2012 |
| 22439938 | Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. | Cancer Cell | 2012 |
| 22672250 | A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. | BMC Urol | 2012 |
| 22647880 | Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. | Epigenetics | 2012 |
| 22278882 | DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. | Nucleic Acids Res | 2012 |
| 22391556 | A DNA hypermethylation module for the stem/progenitor cell signature of cancer. | Genome Res | 2012 |
| 21278247 | Genomic and epigenomic integration identifies a prognostic signature in colon cancer. | Clin Cancer Res | 2011 |
| 29776209 | Epigenetic-based companion diagnostics. | Per Med | 2011 |
| 22094255 | Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. | Cancer Cell | 2011 |
| 21154739 | Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. | Int J Cancer | 2011 |
| 19821512 | High content image cytometry in the context of subnuclear organization. | Cytometry A | 2010 |
| 20697356 | Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. | Oncogene | 2010 |
| 20841480 | Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. | Cancer Res | 2010 |
| 20830311 | Array-based DNA methylation profiling for breast cancer subtype discrimination. | PLoS One | 2010 |
| 20736368 | Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. | Cancer Res | 2010 |
| 20562917 | Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. | Oncogene | 2010 |
| 20042676 | Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. | Am J Pathol | 2010 |
| 19435926 | Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. | Cancer Res | 2009 |
| 19602592 | Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. | Cancer Res | 2009 |